cjc1295 no dac / ipamorelin CJC-1295 (No DAC) (5mg) (5mg) – YOUR TRUSTED SOURCE OF PEPTIDES Third party lab tested with a certificate of analysis Ipamorelin/CJC-1295 (no DAC) 5MG/5MG |

We will also examine how it may influence the results of your treatment

Considering its potential impact on ghrelin receptors, Ipamorelin may enhance appetite, possibly leading to weight gain

At Perfect B, the peptide is sourced from an FDA-registered compounding pharmacy under a valid prescription written after a clinical evaluation

Sergey Terushkin, MD, FACS Key Takeaways: Mounjaro (tirzepatide) targets GIP + GLP-1 receptors , while Ozempic (semaglutide) targets GLP-1 only Clinical studies show greater average weight loss with tirzepatide in many patients Both medications require BMI 30 or 27 with weight-related conditions Common side effects include nausea, GI discomfort, and appetite changes , usually improving with dose adjustment Insurance coverage varies more common for diabetes than weight loss Prescription required treatment must be doctor-guided and medically supervised If you are deciding between Mounjaro and Ozempic for weight loss in 2026, the key difference is that tirzepatide (Mounjaro) activates two metabolic pathways (GIP + GLP-1), while semaglutide (Ozempic) activates one (GLP-1) which may impact weight loss outcomes and tolerability